Hansoh Pharmaceutical Group Company Ltd (3692.HK) stock: key figures, P/E, revenue and dividend

Health Care · China · ISIN KYG549581067

Price
26.69 HKD
Market cap
160.28 bn HKD
P/E (2025)
26.97
P/S (2025)
10.67
Dividend yield
1.55 %
Net margin
36.97 %
Return on equity (ROE)
15.71 %
Return on assets (ROA)
13.92 %

Hansoh Pharmaceutical Group Company Ltd financials

Fiscal year20242025
Revenue12.26 bn CNY15.03 bn CNY
Gross profit9.94 bn CNY14.45 bn CNY
EBIT3.59 bn CNY5.79 bn CNY
Net income4.37 bn CNY5.56 bn CNY
Diluted EPS – continuing operations0.65 CNY0.99 CNY

Full history since 2016, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Hansoh Pharmaceutical Group Company Ltd

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited operates as a subsidiary of Stellar Infinity Company Ltd.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 15.10.2026. Details in the risk notice.

Hansoh Pharmaceutical Group Company Ltd stock (3692.HK): P/E, revenue, dividend | finmetric